Blockchain Registration Transaction Record
Clene Secures $10M Debt Facility for ALS Drug Approval Process
Clene (NASDAQ: CLNN) secures a $10 million debt facility to support the new drug application for lead candidate CNM-Au8 for ALS. CEO Rob Etherington believes this funding will give the company the necessary resources to generate additional data for FDA approval.
This news highlights Clene's progress in securing funding for its drug development efforts, specifically focusing on treating neurodegenerative diseases like ALS. The support of the FDA and the company's strategic financial decisions signify a step forward in potentially providing effective treatment options for patients with debilitating conditions.
Blockchain | Details |
---|---|
Contract Address | 0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71 |
Transaction ID | 0xb7a201bb63a435087c35acbdbcf366d37a825d1493adb55abf065c7847922669 |
Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
Chain | polygon-main |
NewsRamp Digital Fingerprint | chipXVZv-b0811f2593789b7c1706a52c87b955c5 |